EBS
エマージェント・バイオソリューションズ
EBS
エマージェント・バイオソリューションズ
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS).
Emergent BioSolutions cut FY2026 revenue guidance to $645-$675 million after reaffirming a $720-$760 million outlook three months earlier. Levi & Korsinsky is investigating potential securities law vi
Emergent Biosolutions NYSE: EBS reported second-quarter 2026 revenue and adjusted EBITDA above its prior guidance and analyst consensus, driven by accelerated medical countermeasure deliveries to U.S.
Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript